|国家科技期刊平台
首页|期刊导航|中国中医药信息杂志|清肝散结消瘿方治疗桥本甲状腺炎的疗效及初步机制研究

清肝散结消瘿方治疗桥本甲状腺炎的疗效及初步机制研究OACSTPCD

Study on Efficacy and Preliminary Mechanism of Qinggan Sanjie Xiaoying Decoction in the Treatment of Hashimoto's Thyroiditis

中文摘要英文摘要

目的 探究清肝散结消瘿方治疗桥本甲状腺炎肝经郁热、脾虚痰凝证的临床疗效及作用机制.方法 根据患者意愿将70例患者分为对照组和药物组各35例.2组均限碘饮食,药物组予清肝散结消瘿颗粒,每次1袋,2次/d,口服.2组均连续治疗4周.同期选择20例健康人作为健康组.观察2组患者临床疗效,比较2组患者治疗前后中医症状积分、甲状腺抗体滴度水平(TPOAb、TGAb)、甲状腺体积及峡部厚度,比较3组受试者血清IκB激酶α(IKKα)、核因子κB抑制蛋白A(IKBα)、肿瘤坏死因子-α(TNF-α)水平,监测2组患者治疗期间不良反应情况.结果 药物组总有效率为85.71%(30/35),对照组为20.00%(7/35),药物组优于对照组(P<0.05).与本组治疗前比较,药物组治疗后中医症状积分、甲状腺抗体滴度水平、甲状腺体积、甲状腺峡部厚度均明显改善(P<0.05);2组治疗后比较,药物组中医症状积分、甲状腺体积均低于对照组(P<0.05),TPOAb滴度下降率高于对照组(P<0.05).2组患者治疗前IKKα、TNF-α水平均高于健康组,IKBα水平均低于健康组(P<0.05);与本组治疗前比较,药物组治疗后IKKα、TNF-α水平下降,IKBα水平升高(P<0.05);2组治疗后比较,药物组IKKα、TNF-α低于对照组,IKBα高于对照组(P<0.05).2组患者治疗期间未见不良事件.结论 清肝散结消瘿方治疗桥本甲状腺炎可降低抗体滴度水平、减轻甲状腺肿大及峡部厚度、降低中医症状积分,临床安全有效,其可能是通过干预NF-κB信号通路发挥治疗作用.

Objective To explore the clinical efficacy and mechanism of Qinggan Sanjie Xiaoying Decoction in the treatment of Hashimoto's thyroiditis with syndrome of stagnation heat of liver meridian and stagnation of spleen deficiency and phlegm.Methods Totally 70 patients were divided into control group and medicine group according to their wishes,with 35 patients in each group.Both groups were restricted to an iodine diet.The medicine group was given Qinggan Sanjie Xiaoying Granules,1 sachet at a time,twice a day,orally.The treatment for both groups lasted for 4 weeks.20 healthy people were chosen as the healthy group.The clinical efficacy of both groups was observed.TCM symptom score,thyroid antibody titer levels(TPOAb,TGAb),changes in thyroid volume and isthmus of both groups before and after treatment were compared.Levels of serum IKKα,IKBα and TNF-α of the three groups were compared.Adverse reactions of patients daring the treatment period were monitored.Results The total effective rate of the medicine group was 85.71%(30/35),while the control group was 20.00%(7/35).The medicine group was superior to the control group(P<0.05).Compared with before treatment,the medication group showed significant improvement in TCM symptom scores,TPOAb and TGAb titer levels,thyroid volume,and thyroid isthmus thickness after treatment(P<0.05).After treatment,TCM symptom score,thyroid volume in the medicine group were lower than those in the control group(P<0.05),and the decrease rate of TPOAb titer was higher than that in the group(P<0.05).The levels of IKKα and TNF-α before treatment of medicine group and control group were higher than that in the healthy control group,and the level of IKBα was lower than that of the healthy control group(P<0.05);compared with before treatment,the levels of IKKα and TNF-α in the medicine group decreased,and the level of IKBα increased(P<0.05);after treatment,the levels of IKKα and TNF-α in the medicine group were lower than that in the control group,and IKBα was higher than the control group(P<0.05).No adverse events were observed during the treatment period in both groups of patients.Conclusion Qinggan Sanjie Xiaoying Decoction can reduce the antibody titer level,thyroid enlargement,isthmus thickness,and TCM syndrome score in the treatment of Hashimoto's thyroiditis.It is safe and effective in clinical practice.Qinggan Sanjie Xiaoying Decoction may play a therapeutic role by interfering with NF-κB signaling pathway.

李心爱;丁治国;陈晓珩;李哲;祁烁

北京中医药大学东直门医院,北京 100700北京中医药大学孙思邈医院,陕西 铜川 727100||北京中医药大学孙思邈研究院,陕西 铜川 727100||北京中药大学孙思邈医院甲状腺病研究所,陕西 铜川 727100北京中医药大学东直门医院,北京 100700||北京中医药大学孙思邈医院,陕西 铜川 727100||北京中药大学孙思邈医院甲状腺病研究所,陕西 铜川 727100

中医学

桥本甲状腺炎清肝散结消瘿方临床疗效机制中医药

Hashimoto's thyroiditisQinggan Sanjie Xiaoying Decoctionclinical efficacymechanismTCM

《中国中医药信息杂志》 2024 (002)

154-159 / 6

陕西省中医药管理局科研项目(2021-GJ-LC002);铜川市甲状腺病防治中心科研项目(TJF-2022-25);北京中医药大学孙思邈研究院青年培优项目(SSMYJY-3-2021-13)

10.19879/j.cnki.1005-5304.202303248

评论